Youmanitarian 11 Jun 2021

Lecture automatique

Kerrville, Texas flooding update: Several confirmed dead as evacuations, rescue efforts continue alo

Youmanitarian · 24 Vues

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer

7 Vues

TAKE ACTION

Donations would go to support charities for Comment styliser

Dans Comment styliser

Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the KEYNOTE-100 trial (NCT02674061) of pembrolizumab in advanced recurrent ovarian cancer patients. Importantly, no significant difference in response rate was found between heavily and less heavily pretreated patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Montre plus

More ways to take action

Explore ways that you can help bring a solution to this issue.

Create Youms with
hashtags Comment styliser

Create a challenge to
bring awareness to this issue for people to complete

Create a fundraiser to
support a charity that tackle this issue

Volunteer at charitable organization
that support this cause

Create a movement page dedicated to this cause to bring awareness.

Start a uCharity for this cause and invite people to join it to support this cause

Lecture automatique

Kerrville, Texas flooding update: Several confirmed dead as evacuations, rescue efforts continue alo

Youmanitarian · 24 Vues

Suivant

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer

Suivant

Catégories

Veuillez noter que si vous avez moins de 18 ans, vous ne pourrez pas accéder à ce site.

Suivant

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer

Suivant

Catégories

Choisissez une méthode de paiement